Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs

Stock Information for Homology Medicines Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Homology Medicines Inc.

Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting
Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer
STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Homology Medicines, Inc. and Encourages Long-Term FIXX Stockholders to Contact the Firm
Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference
Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium(TM) Meeting
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Homology Medicines, Inc. (FIXX) and Encourages Long-Term FIXX Investors to Contact the Firm
Homology Medicines Reports Third Quarter 2022 Financial Results and Recent Highlights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.